[go: up one dir, main page]

BR0114094A - Imunógeno - Google Patents

Imunógeno

Info

Publication number
BR0114094A
BR0114094A BR0114094-9A BR0114094A BR0114094A BR 0114094 A BR0114094 A BR 0114094A BR 0114094 A BR0114094 A BR 0114094A BR 0114094 A BR0114094 A BR 0114094A
Authority
BR
Brazil
Prior art keywords
immunogen
antibody
relates
hiv
neutralizes
Prior art date
Application number
BR0114094-9A
Other languages
English (en)
Inventor
Barton F Haynes
Dhavalkumar D Patel
Munir Alam
Hua-Xin Liao
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of BR0114094A publication Critical patent/BR0114094A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A61K47/6841—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses the antibody targeting a RNA virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"IMUNóGENO". A presente invenção refere-se, em geral, à um imunógeno e, em particular, imunógeno para indução de anticorpos que neutraliza um espectro amplo, de isolados primários HIV. A invenção também refere-se a um método de indução de anticorpos anti-HIV empregando o mesmo.
BR0114094-9A 2000-09-22 2001-09-24 Imunógeno BR0114094A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23432700P 2000-09-22 2000-09-22
US28517301P 2001-04-23 2001-04-23
US32369701P 2001-09-21 2001-09-21
US32370201P 2001-09-21 2001-09-21
PCT/US2001/029830 WO2002024149A2 (en) 2000-09-22 2001-09-24 Immunogen comprising ligand bound hiv envelpe protein

Publications (1)

Publication Number Publication Date
BR0114094A true BR0114094A (pt) 2003-07-22

Family

ID=27499729

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114094-9A BR0114094A (pt) 2000-09-22 2001-09-24 Imunógeno

Country Status (11)

Country Link
US (2) US7101552B2 (pt)
EP (1) EP1331942A4 (pt)
JP (1) JP2004511444A (pt)
KR (1) KR20030036819A (pt)
CN (1) CN1505528A (pt)
AU (2) AU9466701A (pt)
BR (1) BR0114094A (pt)
CA (1) CA2423127A1 (pt)
IL (1) IL154991A0 (pt)
MX (1) MXPA03002480A (pt)
WO (1) WO2002024149A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030248A1 (en) 1999-10-22 2001-05-03 Reiley Mark A Facet arthroplasty devices and methods
KR20020075789A (ko) 2000-02-04 2002-10-05 듀크 유니버시티 인체 면역결핍 바이러스 백신
US20080213296A1 (en) * 2000-09-22 2008-09-04 Duke University Immunogen
CA2423127A1 (en) 2000-09-22 2002-03-28 Duke University Immunogen comprising ligand bound hiv envelope protein
US7033593B2 (en) 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
DE60237704D1 (de) * 2001-10-16 2010-10-28 Government Of The Us Secretary Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden
US7195768B2 (en) 2001-11-07 2007-03-27 Duke University Polyvalent immunogen
US7172761B2 (en) 2001-11-07 2007-02-06 Duke University Polyvalent immunogen
AU2002363436A1 (en) 2001-11-07 2003-05-19 Duke University Polyvalent immunogen of hiv
AU2003239356B2 (en) * 2002-05-06 2009-06-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies
US7803913B2 (en) * 2002-05-06 2010-09-28 The United States Of America As Represented By The Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
JP2006509496A (ja) 2002-07-23 2006-03-23 デューク・ユニバーシティー ＩｇＧＦｃ／ＨＩＶ−ｇｐ１２０／Ｃ３ｄ融合タンパク質
US7074238B2 (en) 2003-07-08 2006-07-11 Archus Orthopedics, Inc. Prostheses, tools and methods for replacement of natural facet joints with artificial facet joint surfaces
CN102010463A (zh) 2003-09-17 2011-04-13 杜克大学 共有/祖先免疫原
US7406775B2 (en) 2004-04-22 2008-08-05 Archus Orthopedics, Inc. Implantable orthopedic device component selection instrument and methods
US20050249428A1 (en) * 2004-05-07 2005-11-10 Ming-Jun Chen Method of weeding out repeating patterns from programs
AU2005277363A1 (en) 2004-08-18 2006-03-02 Fsi Acquisition Sub, Llc Adjacent level facet arthroplasty devices, spine stabilization systems, and methods
WO2006044410A2 (en) * 2004-10-14 2006-04-27 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services A32 monoclonal antibody fusion proteins for use as hiv inhibitors and vaccines
WO2006050219A2 (en) * 2004-10-29 2006-05-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9925258B2 (en) 2015-10-02 2018-03-27 International Aids Vaccine Initiative Replication-competent VSV-HIV Env vaccines

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013548A (en) 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5993819A (en) 1987-09-08 1999-11-30 Duke University Synthetic vaccine for protection against human immunodeficiency virus infection
US5019387A (en) 1987-09-08 1991-05-28 Duke University Production of antibodies to HIV
US5516632A (en) 1988-02-08 1996-05-14 Duke University Synthetic peptides
US5217473A (en) * 1989-12-05 1993-06-08 Inbae Yoon Multi-functional instruments and stretchable ligating and occluding devices
AU679439B2 (en) 1992-02-10 1997-07-03 Duke University Use of synthetic peptides to induce tolerance to pathogenic T and B cell epitopes of autoantigens
CA2152915A1 (en) * 1992-12-31 1994-07-21 Jonathan M. Gershoni Antibodies directed against binding-associated epitopes
US5843454A (en) 1993-05-07 1998-12-01 Akzo Nobel N.V. HIV immunogenic complexes
PT762895E (pt) 1994-04-29 2002-11-29 Univ Duke Vacina sintetica para proteccao contra a infeccao de virus da imunodeficiencia humana
AU7465696A (en) 1995-10-20 1997-05-07 Duke University Synthetic vaccine for protection against human immunodeficiency virus infection
IL141211A0 (en) * 1998-08-03 2002-02-10 Univ Montana Prevention and treatment of viral disease
KR20020075789A (ko) 2000-02-04 2002-10-05 듀크 유니버시티 인체 면역결핍 바이러스 백신
US7033593B2 (en) 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
CA2423127A1 (en) 2000-09-22 2002-03-28 Duke University Immunogen comprising ligand bound hiv envelope protein
US7172761B2 (en) 2001-11-07 2007-02-06 Duke University Polyvalent immunogen
AU2002363436A1 (en) 2001-11-07 2003-05-19 Duke University Polyvalent immunogen of hiv
US7195768B2 (en) 2001-11-07 2007-03-27 Duke University Polyvalent immunogen
WO2003046137A2 (en) 2001-11-27 2003-06-05 Duke University Hiv envelope v3-ccr5 binding site immunogen
JP2006509496A (ja) 2002-07-23 2006-03-23 デューク・ユニバーシティー ＩｇＧＦｃ／ＨＩＶ−ｇｐ１２０／Ｃ３ｄ融合タンパク質
CA2526339A1 (en) 2003-05-19 2005-02-24 Duke University Polyvalent immunogen
CN102010463A (zh) 2003-09-17 2011-04-13 杜克大学 共有/祖先免疫原

Also Published As

Publication number Publication date
US7070787B2 (en) 2006-07-04
US7101552B2 (en) 2006-09-05
EP1331942A4 (en) 2005-03-16
EP1331942A2 (en) 2003-08-06
KR20030036819A (ko) 2003-05-09
IL154991A0 (en) 2003-10-31
US20020086283A1 (en) 2002-07-04
MXPA03002480A (es) 2004-05-24
AU9466701A (en) 2002-04-02
AU2001294667B2 (en) 2006-08-17
WO2002024149A3 (en) 2002-09-06
CN1505528A (zh) 2004-06-16
WO2002024149A2 (en) 2002-03-28
CA2423127A1 (en) 2002-03-28
US20040039172A1 (en) 2004-02-26
JP2004511444A (ja) 2004-04-15

Similar Documents

Publication Publication Date Title
BR0114094A (pt) Imunógeno
WO2003039470A3 (en) Polyvalent immunogen of hiv
DE69838454D1 (de) Natürlicher menschlicher antikörper
ATE298946T1 (de) Transformator mit integrierter drossel
BR0108210A (pt) Vacina contra o vìrus da imunodeficiência humana
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
GR930100148A (el) Πυλωροπλαστική και πυλωρεκτομική ασπίς.
NO944377D0 (no) Kjölemiddelblandinger
MY107158A (en) 3-arylcarbonyl; -1h-indoles useful as therapeutic agents.
MXPA04001224A (es) Agentes para incrementar la respuesta inmune.
BR9703302A (pt) Aparelho e método para a geração e uso de ìons férricos
BR0113162A (pt) Ariloxialquilaminas nao-imidazóis
BR0312808A (pt) Proteìna de fusão igg fc/hiv-gp120/c3d
WO2005027836A3 (en) Immunogen
EA199900069A1 (ru) Вакцинная композиция против малярии
DK0732965T1 (da) Anordning ved el-ledningspoler
GB0124267D0 (en) "Fabric"
BR0110054A (pt) Componentes de laço previamente ondulados
MX9304026A (es) Dispositivo vibrador para maquinaria.
ES2115022T3 (es) Inmunoensayo de isotiazolonas.
WO2003046137A3 (en) Hiv envelope v3-ccr5 binding site immunogen
PT633928E (pt) Microrganismos processo de preparacao e utilizacao
ES2107198T3 (es) Uso de lectinas para el tratamiento de enfermedades cutaneas.
DK0831881T3 (da) CETP til forøgelse af HDL-cholesterolniveau
BR0107592A (pt) Compostos calcilìticos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A , 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.